Patent number: 10988467
Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
Type:
Grant
Filed:
May 3, 2019
Date of Patent:
April 27, 2021
Assignee:
Glenmark Pharmaceuticals S.A.
Inventors:
Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
Publication number: 20190256508
Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
Type:
Application
Filed:
May 3, 2019
Publication date:
August 22, 2019
Inventors:
Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
Patent number: 10344024
Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
Type:
Grant
Filed:
April 18, 2018
Date of Patent:
July 9, 2019
Assignee:
GLENMARK PHARMACEUTICALS S.A.
Inventors:
Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
Publication number: 20180237428
Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related Sorphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
Type:
Application
Filed:
April 18, 2018
Publication date:
August 23, 2018
Inventors:
Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
Patent number: 9975887
Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
Type:
Grant
Filed:
August 2, 2016
Date of Patent:
May 22, 2018
Assignee:
GLENMARK PHARMACEUTICALS S.A.
Inventors:
Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
Publication number: 20170233380
Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
Type:
Application
Filed:
August 2, 2016
Publication date:
August 17, 2017
Inventors:
Sanjib DAS, Laxmikant A. GHARAT, Rajendra L. HARDE, Sandeep Y. SHELKE, Shailesh R. PARDESHI, Abraham THOMAS, Neelima KHAIRATKAR-JOSHI, Daisy M. SHAH, Malini BAJPAI